KRON News and Press, Kronos Bio Inc. From 05/17/22

SAN MATEO, Calif. and CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious diseases, today announced participation in the H.C. Wainwright Global Investment Conference. ...

Posters include preclinical data on SYK inhibition in combination with targeted agents and demonstrate preclinical anti-tumor activity in acute myeloid leukemia (AML) Additional presentations detail trial designs for Kronos Bio’s Phase 3 registrational study of entospleti...

Kronos Bio  press release (NASDAQ:KRON): Q1 GAAP EPS of -$0.65 beats by $0.01. $315.4 million in cash, cash equivalents and investments as of March 31, 2022, providing expected runway into the second half of 2024 For further details see: Kronos Bio  GAAP EPS of -$0.65 beat...

Preclinical data on CDK9 inhibitor KB-0742 presented at AACR add to evidence of potential activity in MYC-amplified and transcriptionally addicted tumors; company plans to announce RP2D and additional Phase 1 data in Q4 2022 $315.4 million in cash, cash equivalents and investm...

Preclinical data featured in three posters show potential of KB-0742 in triple-negative breast, lung and ovarian cancers, as well as lymphoma and rare, soft-tissue cancers, including sarcoma and chordoma Company will also present data demonstrating the potential of its new liq...

Data include results from preclinical studies of KB-0742 in MYC-amplified cancers, including small-cell lung, triple-negative breast and ovarian, as well as lymphoma Posters also feature data from preclinical chordoma and sarcoma models KB-0742 is being evaluated in an ongoing...

SAN MATEO, Calif. and CAMBRIDGE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious diseases, today announced participation in the Cowen 42nd Annual Health Care Conferenc...

Kronos Bio  press release (NASDAQ:KRON): Q4 GAAP EPS of -$1.13 misses by $0.03. $339.5 million in cash, cash equivalents and investments as of December 31, 2021, providing expected runway into the second half of 2024 For further details see: Kronos Bio  GAAP EPS of -$1.13 ...

Phase 1/2 trial of CDK9 inhibitor KB-0742 continues to enroll patients in the dose escalation stage, with announcement of recommended Phase 2 dose and Phase 1 data expected in Q4 2022 Lanraplenib trial to start in Q1 2022; Phase 3 registrational AGILITY trial of entospletinib un...

SAN MATEO, Calif. and CAMBRIDGE, Mass., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious diseases, today announced the appointment of Dr. Elizabeth Olek, DO, MPH, as senior vice pre...